255 related articles for article (PubMed ID: 29292966)
1. [Goal-directed administration of antidote for reversal of dabigatran anticoagulation].
Lindeman E
Lakartidningen; 2017 Dec; 114():. PubMed ID: 29292966
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Sié P
Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
[TBL] [Abstract][Full Text] [Related]
3. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
[TBL] [Abstract][Full Text] [Related]
4. [Dabigatran specific antidote: new safety level in oral anticoagulation].
MMW Fortschr Med; 2015 Nov; 157(19):78-9. PubMed ID: 26953416
[No Abstract] [Full Text] [Related]
5. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
[TBL] [Abstract][Full Text] [Related]
6. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
7. idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.
Prescrire Int; 2016 Nov; 25(176):260-263. PubMed ID: 30715821
[TBL] [Abstract][Full Text] [Related]
8. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
[TBL] [Abstract][Full Text] [Related]
9. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
[TBL] [Abstract][Full Text] [Related]
10. Idarucizumab (Praxbind)--an antidote for dabigatran.
Med Lett Drugs Ther; 2015 Nov; 57(1482):157-8. PubMed ID: 26583604
[No Abstract] [Full Text] [Related]
11. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
Miyares MA; Kuyumjian Y; Eaves S; Dollard E
J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
[TBL] [Abstract][Full Text] [Related]
12. Idarucizumab: What Should We Know?
Cortese F; Calculli G; Gesualdo M; Cecere A; Zito A; De Vito F; Carbonara R; Carbonara S; Cortese AM; Ciccone MM
Curr Drug Targets; 2018; 19(1):81-88. PubMed ID: 28950812
[TBL] [Abstract][Full Text] [Related]
13. Idarucizumab: First Global Approval.
Burness CB
Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
[TBL] [Abstract][Full Text] [Related]
14. [Administration of idarucizumab in spontaneous intracerebral hemorrhage under dabigatran-therapy].
Bereczki D; Szilágyi G; Kakuk I; Szakács Z; May Z
Ideggyogy Sz; 2017 Sep; 70(9-10):349-353. PubMed ID: 29870627
[TBL] [Abstract][Full Text] [Related]
15. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study.
Levy JH; van Ryn J; Sellke FW; Reilly PA; Elsaesser A; Glund S; Kreuzer J; Weitz JI; Pollack CV
Ann Surg; 2021 Sep; 274(3):e204-e211. PubMed ID: 31599808
[TBL] [Abstract][Full Text] [Related]
17. Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.
Tsai LK; Lin HJ; Chua SK; Liao PC; Yang YP; Chou PC; Lee CW; Lin MJ; Chen HM; Yeh JT; Li YH
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):e27-e33. PubMed ID: 29122465
[TBL] [Abstract][Full Text] [Related]
18. Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
van der Wall SJ; van Rein N; van den Bemt B; Kruip MJHA; Meijer K; Te Boome LCJ; Simmers TA; Alings AMW; Tieleman R; Klok FA; Huisman MV; Westerweel PE
Europace; 2019 Mar; 21(3):414-420. PubMed ID: 30339226
[TBL] [Abstract][Full Text] [Related]
19. Idarucizumab for Reversal of Dabigatran in Early/Emergency Surgeries: A Case Series.
Peacock WF; Grotta JC; Steiner T
J Emerg Med; 2019 Dec; 57(6):e167-e173. PubMed ID: 31662218
[TBL] [Abstract][Full Text] [Related]
20. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
Pollack CV
Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
